| human | Q5 |
| P496 | ORCID iD | 0000-0002-2967-4792 |
| P69 | educated at | Johns Hopkins University | Q193727 |
| University of California, San Diego | Q622664 | ||
| P108 | employer | Massachusetts Eye and Ear Infirmary | Q6784269 |
| P735 | given name | John | Q4925477 |
| John | Q4925477 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q37276953 | Adalimumab for Ocular Inflammation |
| Q35582576 | Adverse effects of smoking on patients with ocular inflammation |
| Q34644606 | Appropriate use and reporting of uncontrolled case series in the medical literature |
| Q50086956 | Authors reply to Letter to the Editor- In response to: Comment on Durrani et al."s "Adalimumab for Ocular Inflammation". |
| Q34436152 | Birdshot retinochoroidopathy: ocular complications and visual impairment |
| Q35059140 | Cataract after glaucoma filtration surgery |
| Q37205804 | Challenges in the design and implementation of the Multicenter Uveitis Steroid Treatment (MUST) Trial--lessons for comparative effectiveness trials |
| Q46725425 | Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy |
| Q24242512 | Comparison of intraocular lens types for cataract surgery in eyes with uveitis |
| Q34258708 | Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis |
| Q33517496 | Cyclophosphamide for ocular inflammatory diseases |
| Q33520584 | Cyclosporine for ocular inflammatory diseases |
| Q34167410 | Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis |
| Q89705261 | Design and Interpretation of Clinic-Based Studies in Uveitis |
| Q35205797 | Diagnosis and treatment of microsporidial keratoconjunctivitis: literature review and case series |
| Q47278031 | Difluprednate 0.05% versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: Pooled Efficacy Analysis of Two Phase 3 Studies |
| Q35017056 | Effect of technique on intraocular pressure after combined cataract and glaucoma surgery: An evidence-based review |
| Q46130106 | Effect of visual impairment on neuropsychological test performance |
| Q38048856 | Epidemiology of Behçet disease |
| Q96684638 | Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic |
| Q46638002 | Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis |
| Q77836811 | HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial |
| Q99613182 | HIV-induced Retinitis |
| Q35835623 | High-dose intravenous corticosteroids for ocular inflammatory diseases |
| Q33518200 | Hypopyon in patients with uveitis |
| Q34784984 | Immune markers predictive of neuropsychiatric symptoms in HIV-infected youth |
| Q73870924 | Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy |
| Q44673170 | Incidence and management of cataract after retinal detachment repair with silicone oil in immune compromised patients with cytomegalovirus retinitis |
| Q35065882 | Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema |
| Q43842749 | Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS. |
| Q91827083 | Infectious corneal ulceration: a proposal for neglected tropical disease status |
| Q34005672 | Interobserver agreement in clinical grading of vitreous haze using alternative grading scales |
| Q52582234 | Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial. |
| Q33346685 | Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence |
| Q46763248 | Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis |
| Q30652690 | Marginal structural models for comparing alternative treatment strategies in ophthalmology using observational data |
| Q30371489 | Medical management of human immunodeficiency virus infection. |
| Q34930756 | Methodologic rigor of clinical trials on surgical management of eyes with coexisting cataract and glaucoma |
| Q33321092 | Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study |
| Q37188529 | Morphologic assessment for glaucoma in the Multicenter Uveitis Steroid Treatment (MUST) trial |
| Q79219425 | Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome |
| Q33521396 | Mycophenolate mofetil for ocular inflammation |
| Q34102383 | Ocular disease in patients with ANCA-positive vasculitis |
| Q33360668 | Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity |
| Q37299519 | Optical coherence tomography evaluation in the Multicenter Uveitis Steroid Treatment (MUST) trial |
| Q33478325 | Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study |
| Q41109814 | Pattern of Pediatric Uveitis Seen at a Tertiary Referral Center from India |
| Q92722330 | Patterns of Uveitis among Patients Attending Jimma University Department of Ophthalmology, Jimma, Ethiopia |
| Q57072240 | Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial |
| Q34624389 | Periocular corticosteroid injections in uveitis: effects and complications |
| Q58577145 | Prevalence and causes of blindness and vision impairment: magnitude, temporal trends and projections in South and Central Asia |
| Q92963683 | Prevalence and causes of vision loss in East Asia in 2015: magnitude, temporal trends and projections |
| Q90765563 | Prevalence and causes of vision loss in sub-Saharan Africa in 2015: magnitude, temporal trends and projections |
| Q33557283 | Prevalence of open-angle glaucoma among adults in the United States |
| Q35319079 | Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial |
| Q33254097 | Recurrent nodular scleritis preceding an adult TINU syndrome |
| Q35895632 | Remission of Intermediate Uveitis: Incidence and Predictive Factors |
| Q34789195 | Response of pediatric uveitis to tumor necrosis factor-α inhibitors |
| Q36248822 | Retinal vascular occlusion in patients infected with human immunodeficiency virus |
| Q34444734 | Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study |
| Q34416516 | Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy |
| Q35873681 | Risk of Retinal Neovascularization in Cases of Uveitis |
| Q44403529 | Risk of Vision Loss in Patients With Cytomegalovirus Retinitis and the Acquired Immunodeficiency Syndrome |
| Q34613114 | Risk of cataract among subjects with acquired immune deficiency syndrome free of ocular opportunistic infections |
| Q34224273 | Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases |
| Q34337589 | Risk of hypotony in noninfectious uveitis |
| Q33934732 | Risk of relapse in primary acute anterior uveitis |
| Q33889295 | Risk of retinal tear or detachment with oral fluoroquinolone use: a cohort study |
| Q91841433 | Standardization of Nomenclature for Ocular Tuberculosis - Results of Collaborative Ocular Tuberculosis Study (COTS) Workshop |
| Q34930780 | Surgical strategies for coexisting glaucoma and cataract: an evidence-based update |
| Q88480981 | THE COLLABORATIVE OCULAR TUBERCULOSIS STUDY (COTS)-1: A Multinational Review of 251 Patients With Tubercular Retinal Vasculitis |
| Q90305618 | Techniques for improving ophthalmic studies performed on administrative databases |
| Q94584024 | The Changing Global Epidemic of HIV and Ocular Disease |
| Q91590963 | The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting Proceedings |
| Q98507637 | The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Descriptive Review of Tubercular Uveitis in Paediatric Population |
| Q96810007 | The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Review of 165 Patients with Tubercular Anterior Uveitis |
| Q102131462 | The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Review of 447 Patients with Tubercular Intermediate Uveitis and Panuveitis |
| Q35733287 | The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis |
| Q47909535 | The effect of cytomegalovirus retinitis on the quality of life of patients with AIDS in the era of highly active antiretroviral therapy |
| Q36814725 | The impact of macular edema on visual function in intermediate, posterior, and panuveitis. |
| Q34286402 | The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics |
| Q84187225 | The need for a revised approach to epidemiological monitoring of the prevalence of visual impairment |
| Q34312693 | The prevalence of refractive errors among adults in the United States, Western Europe, and Australia |
| Q91433348 | Tubercular Uveitis: Nuggets from Collaborative Ocular Tuberculosis Study (COTS)-1 |
| Q96692708 | Twenty-four Month Outcomes in the Collaborative Ocular Tuberculosis Study (COTS)-1: Defining the "Cure" in Ocular Tuberculosis |
| Q91841099 | Visual Acuity Outcome over Time in Non-Infectious Uveitis |
| Q96810037 | Visual Morbidity in Ocular Tuberculosis - Collaborative Ocular Tuberculosis Study (COTS)-1: Report #6 |
Search more.